IGF-1 GENE THERAPY IN EARLY PARKINSON´S DISEASE

DOLCETTI, FRANCO JC; FALOMIR LOCKHART, EUGENIA; HEREÑU, CB; HERRERA, MACARENA LORENA; BELLINI, MJ

Paris

Congreso; International Neurotoxicology Association and Neurotoxicity Society Meeting 2017; 2017

Parkinson´s disease (PD) is a neurodegenerative disorder that results from a progressive dopaminergic neuronal loss. It is considered a multifactorial condition due to the multiplicity of symptoms experienced by patients. While this condition is known for its characteristic motor deficits, patients also have wide variety non-motor symptoms among them, impaired learning and memory deficits which severely affect their quality of life. These non-motor symptoms result from the dysfunction of interconnected systems, including the striatum, the neocortex and the hippocampus. Growth factors are new targets for therapeutical approaches. Insulin-like growth factor-1 (IGF-1) is an endogenous peptide transported across the blood brain barrier that is protective in several brain injury models, including in an animal model of PD